

Supplemental Figures for:

## Analysis of electronic health records reveals medication-related interference on point-of-care urine drug screening assays

Nadia Ayala-Lopez<sup>1</sup>, Jennifer M. Colby<sup>1</sup> and Jacob J. Hughey<sup>2\*</sup>

<sup>1</sup>Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

<sup>2</sup>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

\*Corresponding author ([jakejhughey@gmail.com](mailto:jakejhughey@gmail.com))



## Supplemental Figure 1 (cont.)



Photos of POC test cups from spiking experiments. Liquichek Urine Toxicology Control Level C4 includes all analytes assayed on the test cup except for buprenorphine and oxycodone. The buprenorphine and oxycodone control was based on the high calibrators from Immunalysis. The vehicle cup for labetalol (80% DMSO) and ranitidine (80% DMSO) was the same (although the images are different), because those experiments were run at the same time. Photos were taken with a Samsung Galaxy, with no filters applied. Photos were cropped, but otherwise unaltered.